

Development Pipeline (As of January 31, 2025)

- This table shows clinical studies on indications for which the Sumitomo Pharma Group aims to obtain approval in Japan, U.S., China, or Europe and does not cover all clinical studies.
- The study for the most advanced development stage is listed if there are multiple studies with the same region and indication.
- The development stage is changed when Investigational New Drug Application/amended IND/ Clinical Trial Notification is filed and/or approved by the applicable authority.

1. Psychiatry & Neurology

Brand name/Generic name/Product code		Proposed indication	Region	Development stage
Small molecule	LATUDA®/ lurasidone hydrochloride	(New usage: pediatric) Schizophrenia	Japan	Phase 3
	DSP-0038	Alzheimer's disease psychosis	U.S.	Phase 1
	DSP-0187	Narcolepsy	Japan	Phase 1
	DSP-3456	Treatment resistant depression	U.S.	Phase 1
	DSP-0378	Dravet syndrome, Lennox-Gastaut syndrome	Japan	Phase 1
	DSP-2342	To be determined	U.S.	Phase 1
Regenerative medicine / cell therapy	CT1-DAP001/DSP-1083 (Allogeneic iPS [induced pluripotent stem] cell-derived dopaminergic neural progenitor cells)	Parkinson's disease	Japan	Under preparation for the NDA
			U.S.	Phase 1/2 (Investigator-initiated study)
				Phase 1/2 (Company-sponsored clinical study)
	HLCR011 (Allogeneic iPS cell-derived retinal pigment epithelial cells)	Retinal pigment epithelium tear	Japan	Phase 1/2
	DSP-3077 (Allogeneic iPS cell-derived retinal sheet)	Retinitis pigmentosa	U.S.	Phase 1/2

2. Oncology

Brand name/ Generic name/ Product code	Proposed indication	Region	Development stage
nuvisertib/ TP-3654	Myelofibrosis	U.S., Japan	Phase 1/2
enzomenib/ DSP-5336	Acute myeloid leukemia	U.S., Japan	Phase 1/2
DSP-0390	Glioblastoma	U.S., Japan	Phase 1
SMP-3124	Solid tumors	U.S., Japan	Phase 1/2

3. Others

Brand name/ Generic name/ Product code	Proposed indication	Region	Development stage
KSP-1007	Complicated urinary tract infections and Complicated intra-abdominal infections, Hospital- acquired bacterial pneumonia including ventilator-associated bacterial pneumonia	U.S., Japan	Phase 1
fH1/DSP-0546LP	Influenza	Europe	Phase 1